Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

1.82p
   
  • Change Today:
    -0.035p
  • 52 Week High: 2.61
  • 52 Week Low: 0.85
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 261,574
  • Market Cap: £7.57m
  • RiskGrade: 328

Immupharma Overview

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

1 Day Chart (24-07-2024)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 7.2  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Immupharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 0.08 (6.74) (3.99)p n/a n/a n/a n/a 0.0%
31-Dec-20 0.13 (7.25) 3.43p 3.9 n/a n/a n/a 0.0%
31-Dec-21 0.12 (8.94) (3.25)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (4.46) (1.26)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (3.42) (0.81)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Immupharma Company Announcements

Result of AGM 28-Jun-2024 12:17 RNS
Holding(s) in Company 06-Jun-2024 16:20 RNS
Notice of AGM & Annual Report & Accounts 05-Jun-2024 14:01 RNS

Latest Immupharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Immupharma Market Data

Currency UK Pounds
Share Price 1.82p
Change Today -0.035p
% Change -1.89 %
52 Week High 2.61
52 Week Low 0.85
Volume 261,574
Shares Issued 416.44m
Market Cap £7.57m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
71.9% below the market average71.9% below the market average71.9% below the market average71.9% below the market average71.9% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Price Trend
35.72% below the market average35.72% below the market average35.72% below the market average35.72% below the market average35.72% below the market average
19.23% above the sector average19.23% above the sector average19.23% above the sector average19.23% above the sector average19.23% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 24-Jul-2024

Time Volume / Share Price
15:59 22,500 @ 1.80p
15:40 25,000 @ 1.84p
15:40 58,250 @ 1.83p
14:21 37,245 @ 1.84p
13:26 44,276 @ 1.84p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page